Edition:
United States

Illumina Inc (ILMN.O)

ILMN.O on Nasdaq

170.81USD
28 Mar 2017
Change (% chg)

$-1.48 (-0.86%)
Prev Close
$172.29
Open
$172.04
Day's High
$172.99
Day's Low
$170.66
Volume
888,559
Avg. Vol
1,198,771
52-wk High
$186.88
52-wk Low
$119.37

ILMN.O

Chart for ILMN.O

About

Illumina, Inc. (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc. (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of... (more)

Overall

Beta: 0.82
Market Cap(Mil.): $25,206.03
Shares Outstanding(Mil.): 146.30
Dividend: --
Yield (%): --

Financials

  ILMN.O Industry Sector
P/E (TTM): 55.12 48.04 29.98
EPS (TTM): 3.13 -- --
ROI: 13.16 6.89 13.08
ROE: 22.87 10.85 14.23

BRIEF-Kailos genetics enters into a co-marketing agreement with Illumina

* Illumina will market and promote Kailos Targetrich line of research solutions for pharmacogenetics targets through commercial channels Source text for Eikon: Further company coverage:

Mar 21 2017

Pharma groups file amicus brief in Illumina patent case

Trade groups representing the biotechnology and pharmaceutical industries have asked a federal appeals court to clarify the rules for determining whether arguments not put forth in U.S. Patent and Trademark Office proceedings can be raised later in district court.

Mar 03 2017

BRIEF-Illumina says board increased size of board from 10 to 11 members

* On February 18, 2017, board increased size of board from ten to 11 members and elected John Thompson to board - SEC filing Source text (http://bit.ly/2m4NjYm) Further company coverage:

Feb 21 2017

BRIEF-Illumina says Novaseq's S1, S4 flow cells expected to be available for shipment in Q3 2017

* Illumina Inc- Novaseq's S1 and S4 flow cells have been prioritized and are expected to be available for shipment in Q3 of 2017 - SEC filing

Feb 13 2017

BRIEF-Illumina Q4 non-gaap earnings per share $0.85

* Illumina reports full financial results for fourth quarter and fiscal year 2016

Jan 31 2017

BRIEF-Illumina elects Caroline Dorsa to serve on board

* Illumina Inc - effective as of Jan 26, 2017 increased size of board from nine to ten members and elected Caroline Dorsa to serve on board - SEC filing Source text: (http://bit.ly/2k1ulOq) Further company coverage:

Jan 27 2017

BRIEF-Illumina names Caroline Dorsa to its board of directors

* Illumina names Caroline Dorsa to its board of directors, adding over 30 years of leadership experience in the healthcare, telecommunications and energy industries Source text for Eikon: Further company coverage:

Jan 27 2017

BRIEF-Caredx to acquire SBT Resolver HLA typing products from Illumina

* Caredx to acquire SBT Resolver HLA typing products from Illumina Source text for Eikon: Further company coverage:

Jan 24 2017

BRIEF-Illumina, NRGene collaborate to accelerate development of new molecular breeding tools for cattle to support global food production

* Illumina, NRGene collaborate to accelerate development of new molecular breeding tools for cattle to support global food production Source text for Eikon: Further company coverage:

Jan 12 2017

Judge in gene-sequencing lawsuit blocks Illumina's claim against Cornell

A federal judge in Delaware has blocked biotechnology company Illumina from filing claims that Cornell University employees deceived the U.S. Patent and Trademark Office in order to obtain a gene-sequencing patent that the university accuses Illumina of infringing.

Jan 12 2017

More From Around the Web

Earnings vs. Estimates